Ke‐Neng Chen

机构：Peking University, Peking University Cancer Hospital · ORCID：0000-0002-4353-0568

发表论文 186 篇 · 总被引 6673 次 · h-index 37

代表论文

• Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer (2023 · New England Journal of Medicine · 被引 1092)
• Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer (2024 · JAMA · 被引 361)
• Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 278)
• Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial. (2023 · Journal of Clinical Oncology · 被引 26)
• KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. (2023 · Journal of Clinical Oncology · 被引 21)
• Adjuvant immunotherapy does not improve survival in non–small cell lung cancer with major/complete pathologic response after induction immunotherapy (2024 · Journal of Thoracic and Cardiovascular Surgery · 被引 14)